Eli Lilly and Company· @EliLillyandCo · X·· 12 天前精选AI 评分67
AI 导读
礼来宣布其一款口服新药获FDA批准，用于ESR1突变乳腺癌患者，该药靶向ER+乳腺癌的两个关键驱动因素。礼来在公告中附上链接供了解详情，未披露药品名称、具体适应症人群及临床数据。
推荐理由
礼来官方披露该口服新药获FDA批准用于ESR1突变乳腺癌，并点明其同时靶向ER+乳腺癌的两个关键驱动因素。
正文
Today, the FDA approved Lilly's new oral treatment for people with ESR1-mutated #BreastCancer, which targets two key drivers of ER+ breast cancer. Learn more: https://go.lilly.com/uli9fh
来源：Eli Lilly and Company · x.com